Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
Most children report struggling with health care tasks like monitoring blood glucose and bolusing insulin, but what if an app ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback